REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

5/1/24 7:05:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RGNX alert in real time by email

ROCKVILLE, Md., May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and recent operational highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

Contacts:

Dana Cormack

Corporate Communications

[email protected]

Investors:

Chris Brinzey, ICR Westwicke

339-970-2843

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-8-to-discuss-first-quarter-2024-financial-results-and-recent-operational-highlights-302132540.html

SOURCE REGENXBIO Inc.

Get the next $RGNX alert in real time by email

Recent Analyst Ratings for

$RGNX

Date	Price Target	Rating	Analyst
11/15/2024	$22.00	Overweight	Morgan Stanley
10/10/2024	$18.00	Outperform	Raymond James
6/7/2024	$38.00	Buy	Goldman
3/11/2024	$36.00	Buy	H.C. Wainwright
3/8/2024	$20.00 → $35.00	Sector Perform → Outperform	RBC Capital Mkts
3/6/2024	$37.00	Market Perform → Outperform	Leerink Partners
2/21/2024	$45.00	Outperform	Raymond James
11/1/2023	$35.00	Buy	Stifel

More analyst ratings

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

Chat with this insight

Recent Analyst Ratings for $RGNX

$RGNX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Morgan Stanley resumed coverage on REGENXBIO with a new price target

Raymond James resumed coverage on REGENXBIO with a new price target

Goldman initiated coverage on REGENXBIO with a new price target

$RGNX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Karabelas Argeris N exercised 10,000 shares at a strike of $3.76 and sold $101,052 worth of shares (10,000 units at $10.11) (SEC Form 4)

Chief Financial Officer Chan Mitchell was granted 58,869 shares (SEC Form 4)

SEC Form 3 filed by new insider Chan Mitchell

$RGNX Press Releases

Fastest customizable press release news feed in the world

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

$RGNX SEC Filings

SEC Form 10-Q filed by REGENXBIO Inc.

REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

REGENXBIO Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

$RGNX Market Insights

Live Market Insights

Why Is Clearside Biomedical Stock Gaining Today?

REGENXBIO Expands Its AFFINITY DUCHENNE Trial To Include A New Cohort Of Younger Patients

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy

$RGNX Large Ownership Changes

This live feed shows all institutional transactions in real time.

$RGNX Leadership Updates

Live Leadership Updates

Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

REGENXBIO Announces Leadership Transition

Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors

$RGNX Financials

Live finance-specific insights

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

Recent Analyst Ratings for
$RGNX

$RGNX
Analyst Ratings

$RGNX
Insider Trading

$RGNX
Press Releases

$RGNX
SEC Filings

$RGNX
Market Insights

$RGNX
Large Ownership Changes

$RGNX
Leadership Updates

$RGNX
Financials